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Abstract: After consumption, antibiotic residues and exposed bacteria end up via the feces in
wastewater, and therefore wastewater is believed to play an important role in the spread of
antimicrobial resistance (AMR). We investigated the abundance and AMR profiles of three different
species over a complete wastewater pathway during a one-year sampling campaign, as well as
including antimicrobial consumption and antimicrobial concentrations analysis. A total of 2886 isolates
(997 Escherichia coli, 863 Klebsiella spp., and 1026 Aeromonas spp.) were cultured from the 211 samples
collected. The bacterial AMR profiles mirrored the antimicrobial consumption in the respective
locations, which were highest in the hospital. However, the contribution of hospital wastewater to
AMR found in the wastewater treatment plant (WWTP) was below 10% for all antimicrobials tested.
We found high concentrations (7–8 logs CFU/L) of the three bacterial species in all wastewaters, and
they survived the wastewater treatment (eﬄuent concentrations were around 5 log CFU/L), showing
an increase of E. coli in the receiving river after the WWTP discharge. Although the WWTP had no
effect on the proportion of AMR, bacterial species and antimicrobial residues were still measured in
the eﬄuent, showing the role of wastewater contamination in the environmental surface water.
Keywords: antimicrobial resistance; wastewater pathway; Escherichia coli; Klebsiella spp.;
Aeromonas spp.; bacterial abundance; antimicrobial consumption; clinical wastewater; wastewater
treatment plant; antimicrobial residues
1. Introduction
Antimicrobials are essential to treat bacterial infections. The emergence and spread of antimicrobial
resistance (AMR) has been globally recognised as a serious threat to public health [1]. Additionally,
antimicrobial consumption can lead to alterations in the human microbiota and can select for
antimicrobial resistant bacteria (AMRB). These AMRB and partially metabolized antimicrobials
are excreted into the wastewater with urine and feces and may end up in surface water via the
sewage system.
Microorganisms 2019, 7, 312; doi:10.3390/microorganisms7090312 www.mdpi.com/journal/microorganisms
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Clinical environments, such as hospitals and nursing homes, are hotspots for AMRB [2], however
>80% of the total antimicrobial consumption in the human sector is prescribed in the community in
Europe [3,4]. Although recent studies demonstrated that hospital wastewater contains higher levels of
AMRB, antimicrobial residues and antimicrobial resistance genes (ARGs) [5–7], the impact of hospital
wastewater on antimicrobial resistance found in the receiving wastewater treatment plant (WWTP)
varies per study [5,6]. The question therefore arises whether on-site clinical wastewater treatment
is effective in reducing the release of AMR. Also, the contribution of healthcare institutions and the
general community as sources of AMRB might depend on the bacterial species investigated and its
prevalence in both the general community and healthcare institutions.
WWTP collect domestic wastewater, clinical wastewater, and wastewater from industry. The main
goal of WWTPs is to reduce nitrogen, phosphorus, total suspended solids, and the biological oxygen
demand, but WWTPs are not designed to remove bacteria and micropollutants such as antimicrobial
residues and heavy metals. In the WWTP, many different bacteria are mixed together with pollutants,
creating circumstances that might favour horizontal gene transfer and selection of AMRB [8,9]. Thus,
WWTPs may contribute to the spread of AMRB into the receiving surface water [10].
Contradictory results have been found on the results of WWTP treatment for resistance. The
proportion of AMR has been found to increase [11–13] as well as decrease [14–16] in the eﬄuent.
However, in a recent large study, the same percentage of AMR Escherichia coli was observed in WWTP
influent and eﬄuent [17]. Again, the role of species identity for AMR selection through the WWTP is
yet unknown.
In this study, three different bacterial species were investigated. E. coli is a typical gut bacteria [18]
which has been the foremost indicator for monitoring faecal contamination in water [19]. Klebsiella spp.,
is a common hospital-related pathogen, which has been scarcely investigated in (waste)water. Multidrug
resistant E. coli and Klebsiella spp. are both important human pathogens. In addition, several ARGs
were first discovered in K. pneumoniae, and probably this species plays a key role in the dissemination
of AMR [20]. Aeromonas spp. are abundant in different aquatic environments, they have also been
described as opportunistic pathogens for humans and (aquatic) animals [21], and they are considered
as important vectors for ARGs into the environment [22,23].
The aim of this study was to investigate the AMRB contribution of clinical and non-clinical
wastewater sources to the wastewater chain and their dependence on the antibiotic usage, the fate of
AMRB in the treatment plant, and the impact of WWTP discharges in terms of AMR on the receiving
surface water. For this purpose, the abundance and antimicrobial susceptibility of three bacterial
species, E. coli, Klebsiella spp., and Aeromonas spp., collected from several (waste)water locations:
community, hospital, nursing home, influent and eﬄuent of WWTP, and two surfaces waters, were
studied during a one-year sampling campaign. In addition, results were analysed in relation to the
antimicrobial consumption and antimicrobial concentrations in the water samples.
2. Materials and Methods
2.1. Sampling Locations and Sample Collection
Wastewater samples were taken in the city of Sneek, The Netherlands (33,855 inhabitants) including
the following locations: wastewater from a nursing home (220 beds), a hospital (300 beds), a community
wastewater collection point (80 households), and the influent and eﬄuent of the corresponding
municipal WWTP. The wastewater samples from the community, hospital, and nursing home were
taken from the receiving wells of which neither receive other wastewater nor rainwater. Municipal
wastewater (including industrial wastewater and rain) is treated centrally at a conventional WWTP
(aerobic treatment, 73,000 p.e.), and the eﬄuent is discharged into the Geeuw canal. Twenty-four-hour
samples were collected flow proportionally (WWTP) or time proportionally (for community, hospital,
and nursing home). When a technical failure occurred, a grab sample was taken, which happened once
for influent, community, and hospital and three times for eﬄuent. Grab samples from the wastewaters
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and eﬄuent were excluded from the bacterial concentration calculations and the measurements of
antimicrobial residues and chemical concentrations, but these samples were still used to obtain bacterial
isolates for antimicrobial susceptibility testing. Surface water samples were collected from the receiving
surface water of the Geeuw canal at two locations, 330 m south-west (N 53◦02′15.10”, E 5◦63′72.76”)
and 388 m north-east (N 53◦02′72.15”, E 5◦64′28.97”) from the WWTP discharge point (N 53◦02′38.85”,
E 5◦64′03.20”). The flow direction of the receiving surface water is artificially managed and can
change per hour. In order to state if the sample location was up- or downstream from the WWTP
discharge at the time of sampling, information was obtained from the waterboards. A sampling point
was distinct up- or downstream if the direction of the waterflow had not changed in the 24 h before
sampling. Out of 52 samples collected from the receiving surface water, 26 could be defined as up- or
downstream. In addition, surface water samples were collected from a non-receiving surface water
located in a nature reserve “de Deele” (N 53◦01′91.00”, E 5◦92′00.72”), which was expected to be barely
effected by anthropogenic activities, and was thus considered as a control surface water [24]. Surface
water samples were collected as grab samples at a one-meter distance from the waterside and ~20 cm
depth. The samples were collected in 2017, every four weeks, two days in a row in 2-L high density
polyethylene (HDPE) bottles (VWR, Amsterdam, The Netherlands), and transported cooled to the
laboratory where they were processed the same day.
2.2. Bacterial Identification and Enumeration
Each sample was filtered in a gradient of volumes [25] using the EZ-Fit TM filtration system with
0.45 µm pore size membrane filters (EX-Pak filters, Millipore, Burlington, MA, USA). Membranes were
transferred onto: (a) Simmons citrate agar (Oxoid) to culture Klebsiella spp., followed by incubation
for 40–48 h at 37 ◦C; (b) Aeromonas medium base (RYAN) agar (Oxoid) to culture of Aeromonas spp.,
followed by incubation for 16–24 h at 37 ◦C. After enumerating the colony forming units (CFU), five
to eight presumptive colonies of Klebsiella spp. and Aeromonas spp. were isolated from each sample
and species identification was confirmed using MALDI-TOF MS (BioMérieux Vitek MS). Up to five of
the confirmed isolates per sample were stored for further analysis. A total of 74–87.7% of the tested
isolates were confirmed as Aeromonas spp., and 70.2–88.3% as Klebsiella spp. in the wastewaters, the
WWTP, and receiving surface waters. However, the percentage of confirmed Klebsiella spp. in the
control surface water was rather low (10.75%), and only eight isolates (6.2%) of Klebsiella spp. were
obtained from this location. The Klebsiella spp. identified were either K. pneumoniae or K. oxytoca,
the total amount of Klebsiella spp. was used for the bacterial enumeration. For Aeromonas spp.,
bacteria could not be distinguished at species level. Tryptone Bile X-Glucuronide medium (TBX)
(Oxoid) was used to culture E. coli, and after 16–24 h incubation at 37 ◦C all blue/green colonies were
counted. At random, 159 (16%) isolates collected from wastewater-samples, WWTP, and receiving
surface waters (16–33 isolates per sample) were tested by MALDI-TOF, and 96.7–100% was identified
as E. coli. However, in the control surface water, the percentage of confirmed E. coli isolates was
lower (76.3%). Plates containing up to 100 CFU (Klebsiella spp. and Aeromonas spp.) or 150 CFU
(E. coli) were included for the enumeration. CFU counts were adjusted to the percentages of the
confirmed isolates to determine the bacterial concentrations [25]. Screening and extra CFU counts
for extended-spectrum beta-lactamase (ESBL)-producing E. coli (ESBL-EC) were performed using a
chromogenic media (BioMérieux) for three months (September, October, and November of 2017). The
suspected ESBL-EC colonies were not further confirmed.
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2.3. Antimicrobial Susceptibility Testing
Five isolates of each bacterial species were collected per sample to perform antimicrobial
susceptibility testing (AST), except for the WWTP influent and the surface waters in which it was not
always possible to obtain five isolates of each species per sample. The bacterial isolates were subjected
to AST using the disk diffusion method and the results were interpreted following the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria [26]. The same breakpoint
were applied to Aeromonas spp. as for Enterobacteriaceae [27]. Multi drug resistance (MDR) was
defined according to Magiorakos et al. [28], with resistance against at least one agent in three or more
antimicrobial categories. E. coli and Klebsiella spp. isolates were tested using twelve antimicrobials from
six classes: (1) Penicillins: ampicillin (AMP) and amoxicillin + clavulanic acid (co-amoxiclav, AMC);
(2) cephalosporins: cefuroxime (CXM), ceftazidime (CAZ), and cefotaxime (CTX); (3) folate pathway
inhibitors: trimethoprim (W) and co-trimoxazole (SXT); (4) fluoroquinolones: ciprofloxacin (CIP);
(5) carbapenems: meropenem (MEM); and (6) aminoglycosides: gentamicin (CN) and tobramycin
(TOB). Isolates that showed resistance against ceftazidime and/or cefotaxime, were further investigated
for ESBL phenotypes using the Vitek 2 system with gram negative susceptibility card AST-N344
(BioMérieux) and confirmation by double disk diffusion. Aeromonas spp. susceptibility was tested for
six antimicrobials (all from different classes): ceftazidime (CAZ), co-trimoxazole (SXT), ciprofloxacin
(CIP), meropenem (MEM), gentamicin (CN), and piperacillin (PRL). In addition, information on AST
of K. pneumoniae and E. coli clinical isolates collected from the urine of patients from the investigated
hospital (n = 544 for E. coli and n = 131 for Klebsiella spp.), nursing home (n = 113 for E. coli and n = 22
for Klebsiella spp.), and from general practitioners (GPs) in Sneek (n = 403 for E. coli and n = 66 for
Klebsiella spp.), was gathered for comparison purposes. Resistance data were collected for each species
of one isolate per patient per year.
2.4. Antimicrobial Consumption
Data on antimicrobial consumption in the hospital and nursing home in 2017, from which the
wastewater was sampled, was provided by the hospital pharmacist. The amount of used antimicrobials
was calculated as defined daily doses (DDD) using the Anatomical Therapeutic Chemical (ATC)
classification system for medicines from the WHO, version 2018 [29]. The annual number of bed-days
and admissions in the hospital were obtained from the societal annual report from the hospital [30], and
corrected as reported by Liem et al. [31]. The antimicrobial use at community level was obtained from
the annual Nethmap report [32], using the values of 2016. The antimicrobial use in the hospital, nursing
home, and community is presented in DDD/1000 patient-days (hospital), resident-days (nursing-home),
or inhabitant-days (community).
2.5. Statistical Analyses
We applied the two-sample t-test assuming unequal variances to determine the differences in
CFU-counts between two locations, using Microsoft Excel (Office 365). The difference in bacterial
concentrations between two different locations was considered significant when p > 0.05 and
t-value > t-critical. For the differences in AMR found between two locations, univariate analyses were
performed using the Fisher’s exact or Chi-square (including Yates correction) methods for categorical
variables using Minitab (version 17).
2.6. Contribution of Hospital Wastewater to AMRB in Influent
The contribution of hospital wastewater to AMRB in influent was calculated using the
following equation:
(Hconc × Htotal-volume × HR):(Iconc × Itotal-volume × IR), (1)
in which Hconc is the concentration of bacteria (CFU/L) in hospital and Iconc in influent, Htotal-volume
is the total volume of wastewater (m3/year) produced by hospital and Itotal-volume processed by the
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WWTP, and HR is the percentage of resistant bacteria against a certain antimicrobial in hospital and IR
in influent. Antimicrobials with only one resistant isolate were not included in the calculation.
2.7. Antimicrobial Residues and Chemical Concentrations
The antimicrobial residues and chemicals were measured by liquid chromatography coupled to a
triple–quadruple mass spectrometer (LC/MS–MS, Agilent Technologies 1200 and 6410 series). A sample
of 2 mL was mixed for 30 min (1750 rpm) with 0.2 mL methanol and 0.1 mL modifier (12.8% formic
acid, 0.24 M NH3, and 0.02 M oxalic acid). After 10 min of centrifugation (3773 rcf), 900 µL of the liquid
phase was mixed with 50 µL internal standard (containing trimethoprim-d9, triclosan, fenoprofen,
atenolol, ciprofloxacin-d8, sulfadoxine-d3, and diaveridine) and either 50 µL of milliQ water or 50 µL
of additional standard (containing 6.8 µg of the compound to be measured). Antimicrobials to be
measured were selected based on the antimicrobial consumption in The Netherlands in 2016 [32].
The selected antibiotics comprised: (1) macrolides: azithromycin, clarithromycin, erythromycin,
tilmicosin, and tilosin; (2) (synthetic) fluoroquinolones: ciprofloxacin, ofloxacin, and flumequine;
(3) lincosamides: lincomycin and clindamycin; (4) folate pathway inhibitors: trimethoprim and
sulphamethoxazole; (5) penicillins: amoxicillin, ampicillin, penicillin G and V; (6) cephalosporins:
cefotaxime; (7) tetracyclines: tetracycline, doxycycline, and oxytetracycline; (8) sulfonamides:
sulphadoxin, sulphachloropyridazine, sulphapyridine, and sulphamethazine. The disinfectants
chlorhexidine and triclosan were also measured. From the quaternary ammonium compounds,
benzalkonium chloride (BAC)12 and BAC14, which are often applied in disinfectant products, were
measured. In addition, three potential human markers were measured: gabapentin, sucralose, and
acesulfame. The measured values were multiplied by their recovery rates, which should be in the
range of 60–140%. If recovery rates were not in the range of 60–140%, the measured values were
excluded. The heavy metals copper, cadmium and zinc were measured by ICP-OES using the Perkin




3. Results and Discussion
In total, 211 samples were collected during the sampling campaign in 2017, from which 2886 isolates
(997 E. coli, 863 Klebsiella spp., and 1026 Aeromonas spp.) were obtained. The total number of samples
obtained per location, and the total number of isolates per bacterial species obtained in each location is
shown in Table S1.
3.1. Antibiotic Consumption and Measured Concentrations Were Highest in Hospital
In general, both antimicrobial consumption and measured concentrations of antimicrobial residues
in wastewater were higher in hospital wastewater (Figure 1, Table S2) than wastewater from the
nursing home and the community. It should be noted that the community sampled in this study
(80 households) was only a small part of the whole community, and therefore it is discussable whether
this was representative. The highest trimethoprim consumption was observed in the hospital, however
measured trimethoprim concentrations were occasionally higher in nursing home wastewater than in
hospital wastewater.
Although consumption of penicillins was relatively high in both hospital and nursing home
(not shown), these antimicrobials could not be measured in any of the wastewater samples, because
of their chemical instability [33]. Tetracycline was not used in the hospital, but still it was found
at low concentrations in hospital wastewater (six samples) (Table S2). These tetracycline residues
could originate from outpatients visiting the hospital, as tetracyclines are the second most consumed
antimicrobial group in the community in The Netherlands [4].
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Figure 1. Antimicrobial consumption versus the measured concentrations. The red dots display
the antimicrobial consumption, and the boxplots show the antimicrobial concentration measured in
the wastewater. C = community, H = hospital, N = nursing home, I = influent. The antimicrobial
concentrations measured in community (azithromycin, clindamycin, and clarithromycin) and nursing
home wastewater (azithromycin and clarithromycin) are not shown as these locations contained less
than five samples with decent measurements.
3.2. Concentrations of Resistant Bact ria Mirrored Antimicrobial Consumption
The proportion of AMRB found in wastewater samples generally mirrored the antimicrobial
consumption in the corresponding location (Figure 2).
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Proportions of resistant K. pneumoniae (for resistance to ceftazidime, ciprofloxacin, co-amoxiclav,
tobramycin, gentamycin, trimethoprim, and co-trimoxazole), K. oxytoca (ceftazidime, ciprofloxacin,
co-amoxiclav, tobramycin, gentamycin) were higher in hospital wastewater, in line with the consumption
of these antimicrobials. With the exception of trimethoprim and co-trimoxazole, the percentage of
resistant K. oxytoca isolates (including MDR) was significantly higher in hospital wastewater than in
communal wastewater (p < 0.05). Differences in the percentages of resistant K. pneumoniae between
hospital and communal wastewater were not significant, this may be due to the low number of isolates
retrieved from communal wastewater (n = 27).
The percentage of resistant Aeromonas spp. (including MDR) was significantly higher in the
hospital than in communal wastewater (p < 0.001). In addition, co-trimoxazole and ciprofloxacin
resistance in Aeromonas spp. from nursing home wastewater was significantly higher than from
communal wastewater (p < 0.001).
In contrast to Klebsiella and Aeromonas spp., the differences observed in resistance percentages of
E. coli between clinical and non-clinical wastewater were smaller. Still, resistance against ampicillin
and co-amoxiclav was significantly higher in hospital and nursing home wastewater than in communal
wastewater (p < 0.05 and p < 0.001, respectively). In addition, ciprofloxacin resistant E. coli in nursing
home wastewater were significantly higher than in communal wastewater (p < 0.01). The percentage
of MDR-E. coli was low in all the samples (3% and lower).
In both hospital and nursing home, AMR was generally higher in clinical isolates obtained from
patients than in wastewater isolates, especially for E. coli (Figures S1 and S2). AMR in E. coli and
Klebsiella spp. isolates from GPs in Sneek was also higher than in wastewater isolates, and more similar
to AMR observed in clinical isolates. AMR observed in wastewater therefore reflected AMR in the
general population rather than in clinical patients. Still, resistance in wastewater isolates and in clinical
isolates showed the same trends between hospital, nursing home, and the general community.
The smaller difference in resistance percentages of E. coli in clinical and non-clinical wastewater,
and the bigger difference in resistance percentage of E. coli between clinical isolates and wastewater
isolates, suggest that clinically-related E. coli abundance in wastewater would be diluted by E. coli
from healthy staff and visitors and from patients who are not using antimicrobials. E. coli is part of the
normal gut microbiota [18], in contrast to Klebsiella and Aeromonas spp. which are found in only a part
of the human population and linked to diseases associated with gut microbiome dysbiosis [34–37].
3.3. ESBL in Wastewater
All the MDR-Klebsiella spp. isolates found in hospital wastewater were also confirmed to be
ESBL-producers, which is in agreement with previous studies reporting that most ESBL-producing
Enterobacteriaceae show co-resistance to fluoroquinolones, trimethoprim, and co-trimoxazole and to
some aminoglycosides [38,39].
The bacterial enumeration on ESBL selective media showed that suspected ESBL-EC colonies
were present in almost all studied locations (Figure S3). The amount of ESBL-EC found in the nursing
home wastewater was 4.5 logs lower than the other wastewaters. Other studies showed important
differences on ESBL-EC colonization rates by residents of nursing homes and long term health care
facilities ranging from zero to 23.7% and from zero to 75% [40,41]. The consumption of cephalosporins
was negligible in the nursing-home investigated in this study.
From the E. coli isolates obtained from non-selective media, only a few strains were confirmed
to have the ESBL-EC phenotype (results not shown). The differences in the detection of ESBL-EC
phenotypes with/without selective media illustrated the difficulty to detect rare resistance phenotypes
without using selective media.
3.4. Hospital Wastewater as Source for Antimicrobial Resistance in the WWTP
Although hospital wastewater contained a clearly elevated concentration of resistant bacteria,
the contribution of hospital wastewater to the total number of resistant bacteria in the influent was
Microorganisms 2019, 7, 312 9 of 15
limited to a maximum of 9% (Figure 3). This is because hospital wastewater only represented a small
proportion of the total influent (~1%). Similarly, Buelow et al. described that no difference in the
relative abundance of antimicrobial resistance genes was found in influent from WWTPs with and
without hospital sewage [5]. Therefore, pre-treatment of hospital wastewater before discharge into the
sewage system might only have had a minor impact on the reduction of discharge of AMR that was
being released into the environment from the sewage system.
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Figure 3. Contribution of hospital wastewater to the total wastewater. The contribution of hospital
wastewater to the t tal volume of wa r treated by he wastewater treatment plant (WWTP) w s
approximately 1% (red line). The percentage of antimicrobial r sistant bacteria in influent originating
from hospital wastewater (grey bar plots) w re c lculated as explained in Section 2.5. CN = gentamicin,
AMP = ampicillin, AMC = co-amoxiclav, PRL = pipera illin, CIP = ci rofloxacin, W = trimethoprim,
SXT = co-trimoxazole. Antimicrobials with only one resistant isolate in i fluent were not included in
the calculation.
3.5. All Studied Species Survived WWTP Treatment and Impacted the Receiving River
E. coli, Klebsiella pp., and Aeromonas spp. showed high conc ntrat ons in raw wastewater, ranging
from 7 to 8 logs CFU/L (Figure 4).
The high concentrations of E. coli in the raw wastewaters, which were comparable with the normal
range of E. coli concentrations observed in other studies [42–44], agree with E. coli constituting a
typical gut inhabitant [18]. Although Aeromonas spp. is a normal inhabitant of the intestinal tract of
certain poikilotherms and freshwater fish, they are not considered to be part of the healthy human
flora [36] and are found in stool of a low percentage of the population (2.5–2.6%) [37]. Thus, the high
concentrations of Aeromonas spp. were less expected, although still these results were in agreement
with a recent study [45]. A possible explanation for the high concentrations in wastewater could
be that Aeromonas spp. persist better in the wastewater as they are aquatic bacteria. Aeromonas spp.
has been associated with human diseases, inter alia gastroenteritis [21]. Interestingly, Klebsiella spp.
and Aeromonas spp. were found in significantly higher concentrations in nursing-home wastewater
compared to community, hospital, and influent (p < 0.05). High concentrations of these genera are
only found in particular human populations suffering from diseases associated with a gut microbiome
dysbiosis [34–37], which is also related to aging [46].
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(> 99%) but all species were still present in effluent (~5 log CFU/L). Interestingly, an increase of E. coli 
and Klebsiella spp. concentrations were observed in the surface water downstream of the WWTP 
effluent outlet, which was significant for E. coli (p < 0.05). No significant differences in Aeromonas spp. 
concentrations upstream, downstream, and in control surface waters were observed (Figure 4), which 
is in line with Aeromonas spp. being present in the aquatic environment [47]. 
3.6. Changes in AMR in WWTP, and Influence of WWTP on Surface Water  
Although the concentration of all studied bacteria decreased in the WWTP by around two logs 
(Figure 4,S3), the percentage of resistant isolates in influent and effluent was similar (Figure 5, Table 
S4). Some studies indicated WWTP’s are hotspots for AMR, as the conditions in the WWTP are 
favourable for the propagation of AMRB [48]. A recent study showed that ARGs are decreased after 
wastewater treatment, but the effluents from WWTPs in southern European countries contain more 
Figure 4. The counts of colony forming units (CFU) for the three targeted bacteria per location. The
bacterial counts are shown as log (CFU)/L, n is the number of collected samples used for the CFU
counts. The diamonds within the boxplots represent the mean, the distribution of the CFU counts are
shown as scatterplots.
The concentration of all three bacterial species was significantly reduced after WWTP treatment
(>99%) but all species were still present in eﬄuent (~5 log CFU/L). Interestingly, an increase of E. coli
and Klebsiella spp. concentrations were observed in the surface water downstream of the WWTP
eﬄuent outlet, which was significant for E. coli (p < 0.05). No significant differences in Aeromonas spp.
concentrations upstream, downstream, and in control surface waters were observed (Figure 4), which
is in line with Aeromonas spp. being present in the aquatic environment [47].
3.6. Changes in AMR in WWTP, and Influence of WWTP on Surface Water
Although the concentration of all studied bacteria decreased in the WWTP by around two logs
(Figure 4 and Figure S3), the percentage of resistant isolates in influent and eﬄuent was similar
(Figure 5, Table S4). Some studies indicated WWTP’s are hotspots for AMR, as the conditions in
the WWTP are favourable for the propagation of AMRB [48]. A recent study showed that ARGs are
decreased after wastewater treatment, but the eﬄuents from WWTPs in southern European countries
contain more ARGs than the eﬄuents from WWTPs in northern European countries; in addition
to different antibiotic consumption, temperature differences can be a possible explanation for this
phenomenon [16]. In this study the percentage of resistant bacteria did neither increase nor decrease in
the WWTP, indicating that there was no selection pressure for AMR in this WWTP for the bacterial
species tested in this study. This finding was in concordance with another study which was also
performed in a north-European country [17].
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surface water are shown. The number of isolates tested p r ocation ar shown in bracke s.
Antimicrobial resistance was higher in the receiving surface water compared to the control surface
water (Figure 4 and Figure S3, Table S4). E. coli sistance against amp cillin and trimethoprim and
A romon s spp. re istance again t piperacillin w s significantly high r in receiving surface water
v rsus the non-receiving surface water (p < 0.05). E. coli and Aeromon s spp. isolates resista t against
ciprofloxaci and co-tr moxazol and ESBL-EC were only found in the receiving surface water. Only a
few Kl bsiella spp. were found in the non-receiving surface water, from which on showed resistance
to any of the antimicrobials other than ampicillin.
In the control surfac water, no human markers were detected bove the LOD, demonstrating
that this water was in general less affected by anthropogenic activities. These results confirm that the
presence of AMR, including ESBL-EC, in the surface water sites was linked to human activity.
No significant difference between the percentage of resistant species up- and downstream waters
was observed, however, bacterial enumeration showed that the WWTP had a significant effect on
the concentrations of E. coli in surface water (p > 0.05). Thus, resistant bacteria might also have been
present upstream the eﬄuent site albeit in lower concentrations. Generally, this surface water was also
impacted by human wastewater as it is evident from the presence of human markers upstream of the
eﬄuent discharge. Only a few isolates were retrieved from surface water which made it difficult to
analyse resistance percentages in water up- and downstream from the eﬄuent point.
Almost all antimicrobial concentrations decreased by 50% or more in the WWTP
(Tables S2 and S3). The human markers, heavy metals, and six of the antimicrobial residues could still be
measured in the eﬄuent (Tables S2 and S3), and ciprofloxacin was even measured above the predicted
no-effect concentrations for resistance selection (PNEC) [49]. Although none of the antimicrobials
were measured above the LOD in the surface waters, human markers were found in the receiving
surface water, and the concentration of gabapentin was higher downstream from the eﬄuent point
(p > 0.05, t-test). These results showed that the WWTP was continuously discharging contaminants
as well as resistant bacteria into the surface water, albeit in low concentrations. Environmental
contamination with antimicrobials and other pollutants can contribute to the maintenance and spread
of antimicrobial resistance genes by enhancing selection pressure, depending on the concentration and
bioavailability [50].
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4. Conclusions
This study investigated the abundance of AMRB (E. coli, Klebsiella spp., and Aeromonas spp.),
antimicrobial use, and antimicrobial concentration in clinical and non-clinical wastewater sources,
the WWTP, and surface water. The highest percentage of resistant bacteria was found in the hospital
wastewater, mirroring the hospital antimicrobial consumption and the measured concentrations of
antimicrobials and other chemical compounds. This was also in concordance with AMR observed in
clinical isolates. However, the contribution of the hospital wastewater to the antimicrobial resistance
in influent was overall smaller than 10%, in accordance with the hospital wastewater comprising only
1% of the total wastewater entering the WWTP. While E. coli is often used as a model organism to
study AMR and faecal contamination in (waste)water, Klebsiella spp. and Aeromonas spp. showed
larger differences in resistance percentages between community and hospital wastewater and might
therefore be better tracers for clinical inputs. Overall, concentrations of the three bacterial species
decreased during the wastewater treatment, however all three species survived the treatment and the
proportion of antimicrobial resistant bacteria did not decrease after the WWTP. Moreover, resistant
bacteria and human markers were found in eﬄuent and receiving surface water, demonstrating the
role of the WWTP in the environmental surface water contamination.
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